Adherence, persistence and treatment switching in psoriasis.
Fiorenzo SantoleriFelice MusiccoChiara FulgenzioPaolo AbrateLaura PestrinEnrico PasutGermana ModestiRomina GianniniStefania De RosaMariantonietta PiccoliGrazia MingollaEva ZuzoloPietro GazzolaMartina RopertiGabriella PieriValentina MontresorIsabella MartignoniMarco GamberaRoberto LangellaGabriella TinariConcetta SpoltoreCristina RobertiLetizia Di FabioLaura GrossiFrancesca GuarinoFrancesco De VitaRuggero LasalaAlberto CostantiniPublished in: Immunotherapy (2024)
Aim: This study aims to investigate drug utilization patterns in the treatment of psoriasis (PsO) from 1 to 5 years in a real-life setting with Adalimumab (Ada), Etanercept (Eta), Ustekinumab (Ust), Golimumab (Gol), Ixekizumab (Ixe), Secukinumab (Sec) and Apremilast (Apr). Materials & methods: Data from an observational study were used to calculate adherence using the Proportion of Days Covered (PDC) method and persistence. Results & conclusion: Treatment adherence was found to be good for all the drugs studied across all years of analysis, while persistence was suboptimal, showing a marked decrease from the third year of study onward. In the treatment of PsO, greater attention needs to be paid to treatment persistence.